Establishment Labs Holdings Inc. operates as a medical technology enterprise specializing in the creation and commercialization of devices for aesthetic and reconstructive ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Est. EPS $-0.26 · Revenue $66.79M · 1 analysts
Est. EPS $-0.10 · Revenue $75.99M · 2 analysts
Est. EPS $-1.20 · Revenue $270.14M · 4 analysts
Est. EPS $-0.25 · Revenue $73.64M · 1 analysts
| Metric | Latest | YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength. | QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes. |
|---|---|---|---|
| RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three). | $211.1M | +27.1% | +12.8% |
| Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day. | $-51.1M | +39.6% | +12.2% |
| Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials. | +69.3% | +5.1% | -0.1% |
| Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on). | -18.5% | +38.6% | +41.6% |
| Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales. | -24.2% | +52.5% | +22.2% |
| Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock. | $-57.6M | +22.2% | -221.4% |
| FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine. | -27.3% | +38.8% | -184.9% |
| Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe. | 1123.1% | +164.7% | -31.7% |
| Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking. | 3.04x | -14.5% | +29.8% |
| Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground. | $357.2M | +3.0% | +0.3% |
| Metric | Annual (A vs E) | Annual Surprise | Quarter (A vs E) | Quarter Surprise |
|---|---|---|---|---|
| EPS Surprise | -1.72 vs -1.86 | +7.7% | -0.39 vs -0.26 | -48.7% |
| Revenue Surprise | $211.1M vs $210.4M | +0.3% | $67.5M vs $66.8M | +1.1% |
| Date | Executive | Title | Security | Side | Shares | Price |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | Caldini Filippo | director, officer: Chief Executive Officer | Common Shares | D | 682 | $71.52 |
| Jun 30, 2026 | Gillin Leslie | director | Common Shares | A | 196 | $85.81 |
| Jun 30, 2026 | Custin Ann | director | Common Shares | A | 239 | $85.81 |
| Jun 30, 2026 | LEWIN NICHOLAS SHERIDAN | director | Common Shares | A | 291 | $85.81 |
| Jun 30, 2026 | SCHUTTER EDWARD J | director | Common Shares | A | 216 | $85.81 |
Operator: Good morning. Welcome to Establishment Labs First Quarter 2026 Earnings Call. [Operator Instructions] As a reminder, today's call is being recorded. I will now turn the call over to Malavika William, Global Head of Corporate Communications and Marketing. Please go ahead. Malavika William: Thank you, operator, and thank you, everyone, for joining us. With me today is Peter Caldini, our Chief Executive Officer; and Sandra Harris, our Chief Financial Officer. Following our prepared remarks, we'll take your questions. Before we begin, I would like to remind you that comments made by management during this call will include forward-looking statements within the meaning of federal securities law. These include statements of Establishment Labs' financial outlook and the company's plans and timing for product development and sales. These forward-looking statements are based on management's current expectations and involve risks and uncertainties. For a discussion of the principal risk factors and uncertainties that may affect our performance or cause actual results to differ materially from these statements, I encourage you to review our most recent annual and quarterly reports on Form 10-K and Form 10-Q as well as other SEC filings, which are available on our website at establishmentlabs.com. I'd also like to remind you that our comments may include certain non-GAAP financial measures with respect to our performance, including, but not limited to, sales results, which can be stated on a constant currency basis or EBITDA, which we disclose on an adjusted EBITDA basis. Reconciliations to comparable GAAP financial measures for non-GAAP measures, if available, may be found in today's press release, which is available on our website. The content of this conference call contains time-sensitive information accurate only as of the date of this live broadcast, May 6, 2026. Except as required by law, Establishment Labs undertakes no obligation to revise or otherwise update any statement to reflect events or circumstances after the date of this call. With that, it is my pleasure to turn the call over to Peter. Filippo Caldini: Good morning, and thank you for joining us. Q1 2026 was a strong start to the year with $59.9 million in revenue and adjusted EBITDA of $1.2 million, representing revenue growth of 45% over Q1 2025. The U.S. business continued to outperform with $19.6 million of revenue, a growth of 216% over Q1 2025 and quarter-over-quarter growth of 13.3%. It's worth noting that Q1 is a seasonally light quarter for breast augmentation and reconstruction, so to grow quarter-over-quarter is a testament to the strength and acceleration of our U.S. launch. Outside the U.S., we delivered 15% growth, driven by strong execution on both our direct and distributor markets. Our minimally invasive platform is showing immense promise as well, generating $9.1 million in revenue in Q1. At the same time, we had our third quarter of positive adjusted EBITDA. …
| Name | Title | Compensation | Gender | Year Born | Status |
|---|---|---|---|---|---|
Juan Jose Chacon Quiros | Founder & Executive Director | USD 1,998,680 | Male | 1972 | Active |
Fillipo Peter Caldini | Chief Executive Officer & Director | USD 1,180,533 | Male | 1965 | Active |
Rajbir Singh Denhoy | Senior Vice President of Global Strategy | USD 645,514 | Male | 1970 | Active |
S. Ross Mansbach | General Counsel, Chief Compliance Officer & Chief Human Resources Officer | USD 595,582 | Male | 1967 | Active |
Ivan Bilic | Senior Vice President of Commercial Operations - OUS | — | Male | — | Active |
Malavika William | VP, Global Head of Marketing & Communications | — | Female | — | Active |
Jeff Ehrhard | Senior Vice President & GM of North America | — | Male | — | Active |
Roberto de Mezerville | Chief Technology Officer | — | Male | 1980 | Active |
Cassandra E. Harris | Senior VP & CFO | — | Female | 1973 | Active |
A Wave of Weight-Loss Drugs Is Quietly Creating a Multi-Billion-Dollar Opportunity That Aesthetic Medicine Is Racing to Capture P
Shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA - Get Free Report) have been given an average recommendation of "Moderate Buy" by the nine ratings firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company.
Deutsche Bank AG purchased a new position in shares of Establishment Labs Holdings Inc. (NASDAQ: ESTA) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 128,138 shares of the company's stock, valued at approximately $10,996,000. Deutsche Bank AG owned 0.44%
Establishment Labs Holdings Inc. (ESTA) Q2 2026 Earnings Call Transcript
Establishment Labs NASDAQ: ESTA reported second-quarter revenue growth of 31.7% year over year, driven by continued rapid expansion in the United States, rising adoption of its Minimally Invasive platform and improving operating leverage.
